Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20624
Abstract: e20624Background: Lung cancer has one of the highest incidences of thromboembolic events (TEE) ranging from 8.4 to13.2%. Cisplatin-based chemotherapy in lung cancer is a well-established risk facto... read more here.
Keywords: thromboembolic events; events lung; lung cancer; impact thromboembolic ... See more keywords